Investor Presentaiton
GAAP to non-GAAP reconciliation - Adjusted EBITDA
$ in millions
Net cash provided by operating activities (GAAP)
Adjustments:
FY 2021
2,018
FY 2020
2,035
Proceeds from available for sales debt securities
63
3
Distributions from equity method investees - investing
1
15
Interest paid, net
127
95
Development-stage funding payments - ongoing
7
20
20
Development-stage funding payments - upfront and milestones
193
6
Termination payments on derivative instruments
16
35
Distributions to non-controlling interests
(480)
(544)
Derivative collateral received, net
Adjusted EBITDA (non-GAAP)(1)
(45)
1,944
1,621
Amounts may not add due to rounding
112
ROYALTY PHARMA
(1) Refer to slide 114 for definitions. Refer to Royalty Pharma's Current Reports on Form 8-K filed with the SEC on February 15, 2022 and May 5, 2022 for additional discussion.View entire presentation